Hepatitis C - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C Pipeline Review, H2 2016, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis C (Infectious Disease) therape